Phase 3 study demonstrated that efanesoctocog alfa met both primary and secondary endpoints
Research concerns ACD440 – a non-opioid drug which treats peripheral neuropathic pain
Amber-UI presents a significant opportunity to treat urge and mixed urinary incontinence
Therapy involves renal transplant patients requiring treatment of BK polyomavirus infection